CASZ1 and glioma: Low expression of CASZ1 in hepatocellular carcinoma, colorectal cancer, esophageal cancer, lung adenocarcinoma and clear cell renal cell carcinoma is associated with poor prognosis, while high expression of CASZ1 in glioma, EOC and lung cancer promotes cancer progression.